333 related articles for article (PubMed ID: 28085016)
41. The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies.
Stein N; Tsukerman P; Mandelboim O
Hum Antibodies; 2017; 25(3-4):111-119. PubMed ID: 28035916
[TBL] [Abstract][Full Text] [Related]
42. Ligand-Blocking and Membrane-Proximal Domain Targeting Anti-OX40 Antibodies Mediate Potent T Cell-Stimulatory and Anti-Tumor Activity.
Zhang P; Tu GH; Wei J; Santiago P; Larrabee LR; Liao-Chan S; Mistry T; Chu ML; Sai T; Lindquist K; Long H; Chaparro-Riggers J; Salek-Ardakani S; Yeung YA
Cell Rep; 2019 Jun; 27(11):3117-3123.e5. PubMed ID: 31189099
[TBL] [Abstract][Full Text] [Related]
43. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.
Qi X; Li F; Wu Y; Cheng C; Han P; Wang J; Yang X
Nat Commun; 2019 May; 10(1):2141. PubMed ID: 31105267
[TBL] [Abstract][Full Text] [Related]
44. The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity.
He Y; Vlaming M; van Meerten T; Bremer E
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053463
[TBL] [Abstract][Full Text] [Related]
45. Anti-GITR antibodies--potential clinical applications for tumor immunotherapy.
Schaer DA; Cohen AD; Wolchok JD
Curr Opin Investig Drugs; 2010 Dec; 11(12):1378-86. PubMed ID: 21154120
[TBL] [Abstract][Full Text] [Related]
46. Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
Cheuk AT; Mufti GJ; Guinn BA
Cancer Gene Ther; 2004 Mar; 11(3):215-26. PubMed ID: 14671675
[TBL] [Abstract][Full Text] [Related]
47. Modulation of CTLA-4 and GITR for cancer immunotherapy.
Avogadri F; Yuan J; Yang A; Schaer D; Wolchok JD
Curr Top Microbiol Immunol; 2011; 344():211-44. PubMed ID: 20563707
[TBL] [Abstract][Full Text] [Related]
48. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
49. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
[TBL] [Abstract][Full Text] [Related]
50. TNFRs and Control of Chronic LCMV Infection: Implications for Therapy.
Clouthier DL; Watts TH
Trends Immunol; 2015 Nov; 36(11):697-708. PubMed ID: 26481667
[TBL] [Abstract][Full Text] [Related]
51. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.
Li F; Ravetch JV
Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10966-71. PubMed ID: 22723355
[TBL] [Abstract][Full Text] [Related]
52. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
Chester C; Sanmamed MF; Wang J; Melero I
Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
[TBL] [Abstract][Full Text] [Related]
53. Analysis of FcγR-Dependent Agonism of Antibodies Specific for Receptors of the Tumor Necrosis Factor (TNF) Receptor Superfamily (TNFRSF).
Medler J; Wajant H
Methods Mol Biol; 2021; 2248():81-90. PubMed ID: 33185869
[TBL] [Abstract][Full Text] [Related]
54. Role of 4-1BB in immune responses.
Vinay DS; Kwon BS
Semin Immunol; 1998 Dec; 10(6):481-9. PubMed ID: 9826581
[TBL] [Abstract][Full Text] [Related]
55. The immunological synapse as a pharmacological target.
Finetti F; Baldari CT
Pharmacol Res; 2018 Aug; 134():118-133. PubMed ID: 29898412
[TBL] [Abstract][Full Text] [Related]
56. Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade.
Wilkinson RW; Leishman AJ
Front Immunol; 2018; 9():1082. PubMed ID: 29910800
[TBL] [Abstract][Full Text] [Related]
57. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses.
Chen M; Ouyang H; Zhou S; Li J; Ye Y
Cell Immunol; 2014 Feb; 287(2):91-9. PubMed ID: 24487032
[TBL] [Abstract][Full Text] [Related]
58. Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking.
Liu L; Wu Y; Ye K; Cai M; Zhuang G; Wang J
Front Pharmacol; 2022; 13():924197. PubMed ID: 35865955
[TBL] [Abstract][Full Text] [Related]
59. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
60. [Relationship between OX40/4-1 BB (CD134/CD137) costimulatory molecules expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease].
Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(3):133-40. PubMed ID: 16232366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]